Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
10 results:

  • 1. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
    Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Single nucleotide polymorphisms within MUC4 are associated with colorectal cancer survival.
    Lu S; Catalano C; Huhn S; Pardini B; Partu L; Vymetalkova V; Vodickova L; Levy M; Buchler T; Hemminki K; Vodicka P; Försti A
    PLoS One; 2019; 14(5):e0216666. PubMed ID: 31091244
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.
    Lin PC; Yeh YM; Wu PY; Hsu KF; Chang JY; Shen MR
    Sci Rep; 2019 Mar; 9(1):3931. PubMed ID: 30850667
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Murgioni S; Rossini D; Marmorino F; Mennitto A; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
    Ann Oncol; 2017 May; 28(5):1015-1022. PubMed ID: 28453695
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A 19-Gene expression signature as a predictor of survival in colorectal cancer.
    Abdul Aziz NA; Mokhtar NM; Harun R; Mollah MM; Mohamed Rose I; Sagap I; Mohd Tamil A; Wan Ngah WZ; Jamal R
    BMC Med Genomics; 2016 Sep; 9(1):58. PubMed ID: 27609023
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.
    Zhang YQ; Pilyugin M; Kuester D; Leoni VP; Li L; Casula G; Zorcolo L; Schneider-Stock R; Atzori L; Irminger-Finger I
    Br J Cancer; 2012 Aug; 107(4):675-83. PubMed ID: 22814582
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. BARD1 expression predicts outcome in colon cancer.
    Sporn JC; Hothorn T; Jung B
    Clin Cancer Res; 2011 Aug; 17(16):5451-62. PubMed ID: 21693656
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hereditary risk of women's cancers.
    Frank TS; Critchfield GC
    Best Pract Res Clin Obstet Gynaecol; 2002 Oct; 16(5):703-13. PubMed ID: 12475549
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.